Market Intel: After A Year Of Partnerships, Insulin Pump Manufacturers Will Face Fierce Competition In 2020
The insulin pump market is expected to grow to $5.1bn by 2023, driven by the increasing incidence of diabetes and adoption of next-generation hybrid closed-loop systems, which allow patients and health-care providers to better manage care. This first part of a two-part series highlights the rising competitive landscape of the four major players, Medtronic, Insulet, Tandem Diabetes Care and Valeritas, with insights from endocrinologists. The second part will look at the smaller players, which are gearing up to introduce new products in 2020.
You may also be interested in...
The global insulin pump market is expected to see double-digit growth, reaching $5.1bn in 2024, with product launches expected by Medtronic, Insulet, Tandem and smaller players in 2021.
Roche’s sales in 2020 increased by 1%, at constant exchange rates, to CHF 58.3bn, led by 14% growth in its diagnostics division.
Medtronic will launch its next-generation MiniMed 780G insulin pump while continuing to develop complementary technologies to close the competitive gap with its rivals in the diabetes market.